COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00865644
Recruitment Status : Completed
First Posted : March 19, 2009
Last Update Posted : January 10, 2017
Information provided by (Responsible Party):
Scott Randall Plotkin, MD, PhD, Massachusetts General Hospital

Brief Summary:
The purpose of this study is to determine if imiquimod cream can reverse the growth of neurofibromas. Imiquimod is a skin cream that works by stimulating the body's immune system to respond to tumors. Imiquimod cream is approved for use in patients with various skin lesions, including actinic keratosis, superficial basal cell carcinoma, and external genital warts. Information from these studies, as well as previous laboratory studies, suggest that imiquimod cream may help shrink neurofibromas or keep them from growing.

Condition or disease Intervention/treatment Phase
Neurofibromatosis Type 1 Cutaneous Neurofibromas Drug: Imiquimod 5% Cream Phase 1

Detailed Description:
  • Three of the participant's tumors will be treated with imiquimod cream and one tumor (out of all the remaining tumors) will be followed without treatment (control tumor).
  • Participants will be given a tube of imiquimod cream and be asked to apply it to the three tumors 5 times per week, for a full 6 weeks (Monday through Friday).
  • Participants will be required to come to the hospital for examinations on Week 1, 2, 4 and 6 (+/- 3 calendar days) and after their last dose of imiquimod cream on Weeks 9, 12 and 18 (+/- 5 calendar days. The following tests and procedures will be performed: skin test; vital signs and measurements and photographs of the tumors. Participants will be asked to participate in an optional skin biopsy on Week 4 and research blood tests wil lbe taken on Day 1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1
Study Start Date : March 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: Imiquimod Drug: Imiquimod 5% Cream
Applied topically to three tumors 5 times per week for a full 6 weeks

Primary Outcome Measures :
  1. To determine the effect of topical imiquimod 5% cream on tumor volume of cutaneous neurofibromas in adult subjects with neurofibromatosis 1 [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. To correlate the inflammatory infiltrate adjacent to treated lesions during treatment with tumor response and to determine the number of circulating Tregs in this patient population [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a diagnosis of NF1 based on NIH criterial with two or more of the following characteristics:

    • six or more cafe-au-lait macules (1.5cm or greater in size)
    • skin fold freckling in the axilla or groin
    • optic pathway glioma
    • two or more Lisch nodules of the iris
    • distinctive bony lesions such as dysplasia of the sphenoid wing or of a long bone such as the tibia
    • two or more neurofibromas of any type of 1 or more plexiform neurofibroma
    • first degree relative with NF1
  • Participants must have at least four cutaneous neurofibromas on skin exam with the following qualities:

    • the lesion must be discrete by clinical exam and must not be contact with another skin tumor
    • the lesion must be amenable to measurement with calipers with minimum dimension of 5mm and maximum dimension of 30mm
    • the lesions must be located on the trunk, neck, or extremities (excluding the hands and feet) and must be located in an area that can be photographed
    • histologic confirmation of tumor type is not required in the setting of compatible clinical setting
  • No treatment with an investigation agent for cutaneous neurofibromas within the last 3 months
  • 18 years of age or older

Exclusion Criteria:

  • Pregnant and nursing women
  • Patients who have had chemotherapy or radiotherapy within 6 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 6 weeks earlier
  • Patients may not be receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to imiquimod
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00865644

Layout table for location information
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Scott R. Plotkin, MD, PhD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: Scott Randall Plotkin, MD, PhD, Associate Professor, Massachusetts General Hospital Identifier: NCT00865644    
Other Study ID Numbers: 08-347
First Posted: March 19, 2009    Key Record Dates
Last Update Posted: January 10, 2017
Last Verified: January 2017
Keywords provided by Scott Randall Plotkin, MD, PhD, Massachusetts General Hospital:
imiquimod 5% cream
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurofibromatosis 1
Nerve Sheath Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Nervous System Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Peripheral Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Interferon Inducers